胰岛素缓控释制剂的研究进展  

Research Progress of Insulin Sustained and Controlled Release Preparations

作　　者：李寒梅 王瑶 谢娜 董倩倩 胥茹君 刘迪 陈雪玲 LI Hanmei;WANG Yao;XIE Na;DONG Qianqian;XU Rujun;LIU Di;CHEN Xueling(School of Pharmacy and Bioengineering,Chengdu University,Chengdu 610106,China)

机构地区：[1]成都大学药学与生物工程学院

出　　处：《成都大学学报（自然科学版）》2019年第3期242-246,共5页Journal of Chengdu University（Natural Science Edition）

基　　金：国家自然科学基金(81703448);四川省科技厅应用基础研究(2019YJ0663)资助项目

摘　　要：糖尿病是目前患病率较高的疾病,皮下注射胰岛素是治疗糖尿病的主要方法.天然胰岛素属于多肽蛋白类药物,体内半衰期较短,维持长时间的稳态血药浓度,需要频繁给药,患者的顺应性低.将胰岛素包封在生物相容性好的材料中制成微球或原位植入系统,可在注射部位缓慢持续释放胰岛素,减少注射给药的次数,增加患者的依从性.分析了目前胰岛素注射缓控释制剂的设计思路及相关研究进展.Diabetes is a disease with a high prevalence,and subcutaneous insulin injection is the main method for treating diabetes.Natural insulin belongs to polypeptide protein drugs,has a short half-life in vivo,requires frequent administration to maintain a long-term steady-state blood drug concentration,and has low patient compliance.Insulin is encapsulated in a biocompatible material to form a microsphere or in situ implantation system,so that insulin capsule can slowly and continuously release insulin at the injection site so as to reduce the number of jections and increase patient compliance.This article reviews the current design ideas and research progress of insulin injection controlled release preparations.

关 键 词：胰岛素 缓控释制剂 微粒给药 纳米粒 原位凝胶 

分 类 号：R587.1[医药卫生—内分泌]